Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6370 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A, arm 1 | EXPERIMENTAL | 1\) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food |
| Part A, arm 2 | EXPERIMENTAL | 1\) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food |
| Part B, arm1, 2, and 3 | EXPERIMENTAL | 1. AZD6370 dose x mg o.d. 2. dose x/2 mg b.i.d. 3. dose x/4 mg q.i.d. |
| Part B, arm 4 | EXPERIMENTAL | 4\) Placebo |
| Name | Type | Description |
|---|---|---|
| AZD6370 | DRUG | Oral single doses a+b+c, o.d., suspension |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Treated with diet or metformin. Stable glycemic control indicated by no changed treatment within 3 months * Diabetes Mellitus diagnosis \<5 years Exclusion Criteria: * Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two wee...
Top 20 of 31 competitors
AZD6370 is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD6370 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN.
AZD6370 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. Its clinical program includes a completed Phase 1 trial.
AZD6370 has one completed clinical trial, identified as NCT00690287. This Phase 1 study evaluated the safety, tolerability, and plasma glucose levels after a single oral dose of AZD6370 in patients with Type 2 Diabetes.
AZD6370 is a unique investigational compound and is not known to be the same as any other marketed drug. It is being studied specifically for its potential role in managing Type 2 Diabetes.